- Home
- GORV vs SCYX Comparison
GORV vs SCYX Comparison
Compare GORV & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- SCYX
- Stock Information
- Founded
- GORV 1976
- SCYX 1999
- Country
- GORV United States
- SCYX United States
- Employees
- GORV N/A
- SCYX N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- SCYX Health Care
- Exchange
- GORV Nasdaq
- SCYX Nasdaq
- Market Cap
- GORV 25.3M
- SCYX 28.5M
- IPO Year
- GORV 2015
- SCYX 2014
- Fundamental
- Price
- GORV $0.24
- SCYX $0.70
- Analyst Decision
- GORV Hold
- SCYX
- Analyst Count
- GORV 2
- SCYX 0
- Target Price
- GORV $2.00
- SCYX N/A
- AVG Volume (30 Days)
- GORV 2.3M
- SCYX 138.2K
- Earning Date
- GORV 08-15-2025
- SCYX 08-07-2025
- Dividend Yield
- GORV N/A
- SCYX N/A
- EPS Growth
- GORV N/A
- SCYX N/A
- EPS
- GORV N/A
- SCYX N/A
- Revenue
- GORV $767,257,000.00
- SCYX $2,630,000.00
- Revenue This Year
- GORV $15.65
- SCYX $463.61
- Revenue Next Year
- GORV $20.54
- SCYX $310.80
- P/E Ratio
- GORV N/A
- SCYX N/A
- Revenue Growth
- GORV N/A
- SCYX N/A
- 52 Week Low
- GORV $0.13
- SCYX $0.66
- 52 Week High
- GORV $3.56
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- GORV 48.60
- SCYX 38.69
- Support Level
- GORV $0.22
- SCYX $0.67
- Resistance Level
- GORV $0.26
- SCYX $0.75
- Average True Range (ATR)
- GORV 0.02
- SCYX 0.04
- MACD
- GORV 0.00
- SCYX 0.00
- Stochastic Oscillator
- GORV 51.29
- SCYX 33.06
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.